Tag: life sciences
-
Investor Backing Nanotech Drug Discovery Advances
A life science venture investor is funding further development of a lower-cost molecular-level drug discovery process using nanoscale synthetic DNA strands.
-
Biotechs Partner to Boost mRNA Manufacturing
Two companies working in synthetic biology are advancing a new process they say increases the scale and reduces costs of messenger RNA manufacturing.
-
Self-Applied Patch Shown Feasible for Vaccine Delivery
A clinical trial shows a microneedle patch device for vaccine delivery applied by participants to their own arms works as well in the skin as when administered by clinicians.
-
T-Cell Biotech Gains €17.5M in Grant, Equity Funds
A developer of engineered immune cells to treat cancer and immune deficiencies is raising €17.5 million ($US 19.1 million) in equity and grant funding from an EU agency.
-
Chewable Covid-19 Drug Reduces Viral Load, Symptoms
Clinical trial results show an experimental drug given as a chewable tablet reduces viral load and symptoms in people with mild to moderate Covid-19 disease.
-
$50M Challenge Seeks Quantum Life Science Applications
A new challenge competition seeks life science research applications for quantum computing that take advantage of the technology’s unique computational properties.
-
Industry, Academic Labs Detailing ALS Treatment Actions
Researchers from a developer of neurodegenerative disease therapies and university medical center are investigating the precise workings of a promising ALS treatment.
-
Screening Device Company Kicks-Off Type 1 Diabetes Network
A developer of a blood-testing device that screens for kidney disease risks is the first company to join a network to advance new technology for type 1 diabetes.
-
Moderna, Biotech Partner on Non-Viral Genetic Drug Delivery
Two biotechnology companies are collaborating on creating genetic therapies delivered with lipid nanoscale particles using non-viral mechanisms to reach target cells.
-
Start-Up Licenses Protein Therapy Tech, Raises $50M
A new company making antibodies that degrade disease-causing proteins on and outside cell surfaces is raising $50 million in its first venture funding round.